---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003110"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:12:49.526142+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Coherus reports FY2023 revenue $257.2M, divests CIMERLI to Sandoz for $170M, plans debt paydown

## Summary
- Q4 2023 net revenue $91.5M (+102% YoY); FY2023 $257.2M (+22% YoY); net loss $79.7M Q4, $237.9M FY.
- Closed ophthalmology divestiture to Sandoz on March 1 for $170M upfront plus $17.8M inventory/assets.
- Plans to prepay $175M of $250M term loan by April 1, cutting interest ~70%; workforce reduction of 30%.
- Launched LOQTORZI (NPC) and UDENYCA ONBODY in Q1 2024; UDENYCA market share 26% as of March 1.
- 2024 guidance: SG&A+R&D $250-265M (down from $301.5M in 2023); annual cost savings >$25M.

## SEC filing metadata
- accession: 0001558370-24-003110
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024003110/0001558370-24-003110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024003110/chrs-20240313x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003110
- JSON: https://secwatch.observer/filing/0001558370-24-003110.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003110.txt

## Key facts
- Earnings Releases
  Coherus Oncology, Inc. reported financial results for fiscal year ended December 31, 2023.
  - Period: fiscal year ended December 31, 2023
  - Result: reported results
  source text: On March 13, 2024, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837024003110/0001558370-24-003110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.